List of Excipients in API NALTREXONE
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing NALTREXONE
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| PD-Rx Pharmaceuticals Inc | CONTRAVE | naltrexone hydrochloride and bupropion hydrochloride | 43063-772 | ANHYDROUS LACTOSE | 2024-04-21 |
| PD-Rx Pharmaceuticals Inc | CONTRAVE | naltrexone hydrochloride and bupropion hydrochloride | 43063-772 | CELLULOSE, MICROCRYSTALLINE | 2024-04-21 |
| PD-Rx Pharmaceuticals Inc | CONTRAVE | naltrexone hydrochloride and bupropion hydrochloride | 43063-772 | CROSPOVIDONE | 2024-04-21 |
| PD-Rx Pharmaceuticals Inc | CONTRAVE | naltrexone hydrochloride and bupropion hydrochloride | 43063-772 | CYSTEINE HYDROCHLORIDE | 2024-04-21 |
| PD-Rx Pharmaceuticals Inc | CONTRAVE | naltrexone hydrochloride and bupropion hydrochloride | 43063-772 | EDETATE DISODIUM | 2024-04-21 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing NALTREXONE
| Company | Ingredient | NDC | Excipient |
|---|---|---|---|
| SpecGx LLC | naltrexone hydrochloride | 0406-1170 | CELLULOSE, MICROCRYSTALLINE |
| SpecGx LLC | naltrexone hydrochloride | 0406-1170 | CROSPOVIDONE |
| SpecGx LLC | naltrexone hydrochloride | 0406-1170 | FERRIC OXIDE RED |
| SpecGx LLC | naltrexone hydrochloride | 0406-1170 | FERRIC OXIDE YELLOW |
| SpecGx LLC | naltrexone hydrochloride | 0406-1170 | HYPROMELLOSE |
| >Company | >Ingredient | >NDC | >Excipient |
Detailed excipient profiles for NALTREXONE
Excipient focus: ANHYDROUS LACTOSE
NALTREXONE drug variants containing ANHYDROUS LACTOSE
NALTREXONE drug variants not containing ANHYDROUS LACTOSE
Excipient focus: CELLULOSE, MICROCRYSTALLINE
NALTREXONE drug variants containing CELLULOSE, MICROCRYSTALLINE
NALTREXONE drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Heritage Pharmaceuticals Inc d/b/a Avet Pharmaceuticals Inc | naltrexone hydrochloride | 23155-886 |
| Chartwell RX LLC | naltrexone hydrochloride | 62135-242 |
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
NALTREXONE drug variants containing CROSCARMELLOSE SODIUM
NALTREXONE drug variants not containing CROSCARMELLOSE SODIUM
Excipient focus: CROSPOVIDONE
NALTREXONE drug variants containing CROSPOVIDONE
NALTREXONE drug variants not containing CROSPOVIDONE
Excipient focus: CYSTEINE HYDROCHLORIDE
NALTREXONE drug variants containing CYSTEINE HYDROCHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| PD-Rx Pharmaceuticals Inc | naltrexone hydrochloride and bupropion hydrochloride | 43063-772 |
| Nalpropion Pharmaceuticals LLC | naltrexone hydrochloride and bupropion hydrochloride | 51267-890 |
| >Company | >Ingredient | >NDC |
NALTREXONE drug variants not containing CYSTEINE HYDROCHLORIDE
Excipient focus: EDETATE DISODIUM
NALTREXONE drug variants containing EDETATE DISODIUM
| Company | Ingredient | NDC |
|---|---|---|
| PD-Rx Pharmaceuticals Inc | naltrexone hydrochloride and bupropion hydrochloride | 43063-772 |
| Nalpropion Pharmaceuticals LLC | naltrexone hydrochloride and bupropion hydrochloride | 51267-890 |
| >Company | >Ingredient | >NDC |
NALTREXONE drug variants not containing EDETATE DISODIUM
Excipient focus: FD&C BLUE NO. 2
NALTREXONE drug variants containing FD&C BLUE NO. 2
| Company | Ingredient | NDC |
|---|---|---|
| PD-Rx Pharmaceuticals Inc | naltrexone hydrochloride and bupropion hydrochloride | 43063-772 |
| Nalpropion Pharmaceuticals LLC | naltrexone hydrochloride and bupropion hydrochloride | 51267-890 |
| >Company | >Ingredient | >NDC |
NALTREXONE drug variants not containing FD&C BLUE NO. 2
Excipient focus: FERRIC OXIDE RED
NALTREXONE drug variants containing FERRIC OXIDE RED
NALTREXONE drug variants not containing FERRIC OXIDE RED
Excipient focus: FERRIC OXIDE YELLOW
NALTREXONE drug variants containing FERRIC OXIDE YELLOW
NALTREXONE drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| PD-Rx Pharmaceuticals Inc | naltrexone hydrochloride and bupropion hydrochloride | 43063-772 |
| Nalpropion Pharmaceuticals LLC | naltrexone hydrochloride and bupropion hydrochloride | 51267-890 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
NALTREXONE drug variants containing HYDROXYPROPYL CELLULOSE
NALTREXONE drug variants not containing HYDROXYPROPYL CELLULOSE
Excipient focus: HYPROMELLOSE
NALTREXONE drug variants containing HYPROMELLOSE
NALTREXONE drug variants not containing HYPROMELLOSE
Excipient focus: HYPROMELLOSE 2910
NALTREXONE drug variants containing HYPROMELLOSE 2910
NALTREXONE drug variants not containing HYPROMELLOSE 2910
Excipient focus: HYPROMELLOSES
NALTREXONE drug variants containing HYPROMELLOSES
NALTREXONE drug variants not containing HYPROMELLOSES
Excipient focus: LACTOSE MONOHYDRATE
NALTREXONE drug variants containing LACTOSE MONOHYDRATE
NALTREXONE drug variants not containing LACTOSE MONOHYDRATE
Excipient focus: MAGNESIUM STEARATE
NALTREXONE drug variants containing MAGNESIUM STEARATE
NALTREXONE drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
NALTREXONE drug variants containing POLYETHYLENE GLYCOL
NALTREXONE drug variants not containing POLYETHYLENE GLYCOL
Excipient focus: POLYETHYLENE GLYCOL 400
NALTREXONE drug variants containing POLYETHYLENE GLYCOL 400
NALTREXONE drug variants not containing POLYETHYLENE GLYCOL 400
Excipient focus: POLYETHYLENE GLYCOLS
NALTREXONE drug variants containing POLYETHYLENE GLYCOLS
| Company | Ingredient | NDC |
|---|---|---|
| Aidarex Pharmaceuticals LLC | naltrexone hydrochloride | 53217-261 |
| >Company | >Ingredient | >NDC |
NALTREXONE drug variants not containing POLYETHYLENE GLYCOLS
Excipient focus: POLYSORBATE 80
NALTREXONE drug variants containing POLYSORBATE 80
NALTREXONE drug variants not containing POLYSORBATE 80
Excipient focus: SILICON DIOXIDE
NALTREXONE drug variants containing SILICON DIOXIDE
NALTREXONE drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
NALTREXONE drug variants containing TITANIUM DIOXIDE
NALTREXONE drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| PD-Rx Pharmaceuticals Inc | naltrexone hydrochloride and bupropion hydrochloride | 43063-772 |
| Nalpropion Pharmaceuticals LLC | naltrexone hydrochloride and bupropion hydrochloride | 51267-890 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
